Advertisement

Journal of Neurology

, Volume 260, Issue 10, pp 2684–2690 | Cite as

Inherited neuropathies: an update

  • Anna Sagnelli
  • Giuseppe Piscosquito
  • Davide Pareyson
Medical Progress in the Journal of Neurology

Abstract

In this review, progress in hereditary neuropathy research published in the Journal of Neurology over the last 18 months is summarised.

Keywords

Charcot-Marie-Tooth disease Familial amyloid polyneuropathy Mitochondrial disease Tangier disease Allgrove syndrome ARSACS 

Notes

Conflicts of interest

Dr. Davide Pareyson received research funding from ACMT-Rete and Pfizer Italia, and funded travels from Kedrion SpA and Pfizer Italia. He is a member of the Inherited Neuropathy Consortium Rare Disease Clinical Research Consortium funded by the US National Institutes of Health (NINDS/ORD), Muscular Dystrophy Association, and Charcot-Marie-Tooth Association (CMTA). Dr. Giuseppe Piscosquito received funded travels from Pfizer Italia.

References

  1. 1.
    Pareyson D, Marchesi C (2009) Diagnosis, natural history, and management of Charcot-Marie-Tooth disease. Lancet Neurol 8:654–667PubMedCrossRefGoogle Scholar
  2. 2.
    Saporta MA, Shy ME (2013) Inherited peripheral neuropathies. Neurol Clin 31:597–619PubMedCrossRefGoogle Scholar
  3. 3.
    Fischer C, Trajanoski S, Papić L, Windpassinger C, Bernert G, Freilinger M, Schabhüttl M, Arslan-Kirchner M, Javaher-Haghighi P, Plecko B, Senderek J, Rauscher C, Löscher WN, Pieber TR, Janecke AR, Auer-Grumbach M (2012) SNP array-based whole genome homozygosity mapping as the first step to a molecular diagnosis in patients with Charcot-Marie-Tooth disease. J Neurol 259:515–523PubMedCrossRefGoogle Scholar
  4. 4.
    Davidson GL, Murphy SM, Polke JM, Laura M, Salih MAM, Muntoni F, Blake J, Brandner S, Davies N, Horvath R, Price S, Donaghy M, Roberts M, Foulds N, Ramdharry G, Soler D, Lunn MP, Manji H, Davis MB, Houlden H, Reilly MM (2012) Frequency of mutations in the genes associated with hereditary sensory and autonomic neuropathy in a UK cohort. J Neurol 259:1673–1685PubMedCrossRefGoogle Scholar
  5. 5.
    Rotthier A, Baets J, De Vriendt E, Jacobs A, Auer-Grumbach M, Lévy N, Bonello-Palot N, Kilic SS, Weis J, Nascimento A, Swinkels M, Kruyt MC, Jordanova A, De Jonghe P, Timmerman V (2009) Genes for hereditary sensory and autonomic neuropathies: a genotype-phenotype correlation. Brain 132:2699–2711PubMedCrossRefGoogle Scholar
  6. 6.
    Rotthier A, Baets J, Timmerman V, Janssens K (2012) Mechanisms of disease in hereditary sensory and autonomic neuropathies. Nat Rev Neurol 8:73–85PubMedCrossRefGoogle Scholar
  7. 7.
    Coen K, Pareyson D, Auer-Grumbach M, Buyse G, Goemans N, Claeys KG, Verpoorten N, Laurà M, Scaioli V, Salmhofer W, Pieber TR, Nelis E, De Jonghe P, Timmerman V (2006) Novel mutations in the HSN2 gene causing hereditary sensory and autonomic neuropathy type II. Neurology 66:748–751PubMedCrossRefGoogle Scholar
  8. 8.
    Pacheco-Cuellar G, González-Huerta LM, Valdés-Miranda JM, Peláez-González H, Zenteno-Bacheron S, Cazarin-Barrientos J, Cuevas-Covarrubias SA (2011) Hereditary sensory and autonomic neuropathy II due to novel mutation in the HSN2 gene in Mexican families. J Neurol 258:1890–1892PubMedCrossRefGoogle Scholar
  9. 9.
    Shekarabi M, Dion PA, Rouleau GA (2012) Letter to the editors: comment on “hereditary sensory and autonomic neuropathy II due to novel mutation in the HSN2 gene in Mexican families”. J Neurol 259:565–566PubMedCrossRefGoogle Scholar
  10. 10.
    Marttila M, Rautenstrauss B, Huehne K, Laitinen V, Majamaa K, Kärppä M (2012) A novel mutation of myelin protein zero associated with late-onset predominantly axonal Charcot-Marie-Tooth disease. J Neurol 259:1585–1589PubMedCrossRefGoogle Scholar
  11. 11.
    Shy ME, Jani A, Krajewski K, Grandis M, Lewis RA, Li J, Shy RR, Balsamo J, Lilien J, Garbern JY, Kamholz J (2004) Phenotypic clustering in MPZ mutations. Brain 127:371–384PubMedCrossRefGoogle Scholar
  12. 12.
    Laurà M, Milani M, Morbin M, Moggio M, Ripolone M, Jann S, Scaioli V, Taroni F, Pareyson D (2007) Rapid progression of late onset axonal Charcot-Marie-Tooth disease associated with a novel MPZ mutation in the extracellular domain. J Neurol Neurosurg Psychiatry 78:1263–1266PubMedCrossRefGoogle Scholar
  13. 13.
    Ginsberg L, Malik O, Kenton AR, Sharp D, Muddle JR, Davis MB, Winer JB, Orrell RW, King RH (2004) Coexistent hereditary and inflammatory neuropathy. Brain 127:193–202PubMedCrossRefGoogle Scholar
  14. 14.
    Houlden H, Laura M, Ginsberg L, Jungbluth H, Robb SA, Blake J, Robinson S, King RH, Reilly MM (2009) The phenotype of Charcot-Marie-Tooth disease type 4C due to SH3TC2 mutations and possible predisposition to an inflammatory neuropathy. Neuromuscul Disord 19:264–269PubMedCrossRefGoogle Scholar
  15. 15.
    Lewis RA, Sumner AJ, Shy ME (2000) Electrophysiological features of inherited demyelinating neuropathies: a reappraisal in the era of molecular diagnosis. Muscle Nerve 23:1472–1487PubMedCrossRefGoogle Scholar
  16. 16.
    Miki Y, Tomiyama M, Haga R, Nishijima H, Suzuki C, Kurihara A, Sugimoto K, Hashiguchi A, Takashima H, Baba M (2013) A family with IVIg-responsive Charcot–Marie–Tooth disease. J Neurol 260:1147–1151PubMedCrossRefGoogle Scholar
  17. 17.
    Sugimoto T, Ochi K, Hosomi N, Takahashi T, Ueno H, Nakamura T, Nagano Y, Maruyama H, Kohriyama T, Matsumoto M (2013) Ultrasonographic nerve enlargement of the median and ulnar nerves and the cervical nerve roots in patients with demyelinating Charcot-Marie-Tooth disease: distinction from patients with chronic inflammatory demyelinating polyneuropathy. J Neurol. doi: 10.1007/s00415-013-7021-0 Google Scholar
  18. 18.
    Weishaupt JH, Ganser C, Bähr M (2012) Inflammatory demyelinating CNS disorder in a case of X-linked Charcot-Marie-Tooth disease: positive response to natalizumab. J Neurol 259:1967–1969PubMedCrossRefGoogle Scholar
  19. 19.
    Scherer SS, Kleopa KA (2012) X-linked Charcot-Marie-Tooth disease. J Peripher Nerv Syst 17:9–13PubMedCrossRefGoogle Scholar
  20. 20.
    Kwon JY, Chung KW, Park EK, Park SW, Choi BO (2009) Charcot-Marie-Tooth 1A concurrent with schwannomas of the spinal cord and median nerve. J Korean Med Sci 24:763–766PubMedCrossRefGoogle Scholar
  21. 21.
    Heckmann JG, Dütsch M, Buslei R (2007) Hereditary neuropathy with liability to pressure palsy combined with schwannomas of the median and medial plantar nerves. Muscle Nerve 35:122–124PubMedCrossRefGoogle Scholar
  22. 22.
    Toyota K, Ogino D, Hayashi M, Taki M, Saito K, Abe A, Hashimoto T, Umetsu K, Tsukaguchi H, Hayasaka K (2013) INF2 mutations in Charcot-Marie-Tooth disease complicated with focal segmental glomerulosclerosis. J Peripher Nerv Syst 18:97–98PubMedCrossRefGoogle Scholar
  23. 23.
    Ohyagi M, Sanjo N, Yokota T, Mizusawa H (2012) Hereditary neuropathy with liability to pressure palsy combined with suspected schwannomas of the peroneal and radial nerves. J Neurol 259:977–979PubMedCrossRefGoogle Scholar
  24. 24.
    Bäumer P, Mautner VF, Bäumer T, Schuhmann MU, Tatagiba M, Heiland S, Kaestel T, Bendszus M, Pham M (2013) Accumulation of non-compressive fascicular lesions underlies NF2 polyneuropathy. J Neurol 260:38–46PubMedCrossRefGoogle Scholar
  25. 25.
    Planté-Bordeneuve V, Said G (2011) Familial amyloid polyneuropathy. Lancet Neurol 10:1086–1097PubMedCrossRefGoogle Scholar
  26. 26.
    Coelho T, Maia LF, da Silva AM, Cruz MW, Planté-Bordeneuve V, Suhr OB, Conceiçao I, Schmidt HH, Trigo P, Kelly JW, Labaudinière R, Chan J, Packman J, Grogan DR (2013) Long-term effects of tafamidis for the treatment of transthyretin familial amyloid polyneuropathy. J Neurol. doi: 10.1007/s00415-013-7051-7 PubMedGoogle Scholar
  27. 27.
    Adams D (2013) Recent advances in the treatment of familial amyloid polyneuropathy. Ther Adv Neurol Disord 6:129–139PubMedCrossRefGoogle Scholar
  28. 28.
    Coelho T, Adams D, Silva A, Lozeron P, Hawkins PN, Mant T, Perez J, Chiesa J, Warrington S, Tranter E, Munisamy M, Falzone R, Harrop J, Cehelsky J, Bettencourt BR, Geissler M, Butler JS, Sehgal A, Meyers RE, Chen Q, Borland T, Hutabarat RM, Clausen VA, Alvarez R, Fitzgerald K, Gamba-Vitalo C, Nochur SV, Vaishnaw AK, Sah DW, Gollob JA, Suhr OB (2013) Safety and efficacy of RNAi therapy for transthyretin amyloidosis. N Engl J Med 369:819–829PubMedCrossRefGoogle Scholar
  29. 29.
    Briani C, Cavallaro T, Ferrari S, Taioli F, Calamelli S, Verga L, Adami F, Fabrizi GM (2012) Sporadic transthyretin amyloidosis with a novel TTR gene mutation misdiagnosed as primary amyloidosis. J Neurol 259:2226–2228PubMedCrossRefGoogle Scholar
  30. 30.
    Lefaucheur JP, Ng Wing Tin S, Kerschen P, Damy T, Planté-Bordeneuve V (2013) Neurophysiological markers of small fibre neuropathy in TTR-FAP mutation carriers. J Neurol 260:1497–1503PubMedCrossRefGoogle Scholar
  31. 31.
    Joint Task Force of the EFNS and the PNS (2010) European Federation of Neurological Societies/Peripheral Nerve Society Guideline on the use of skin biopsy in the diagnosis of small fiber neuropathy. Report of a joint task force of the European Federation of Neurological Societies and the Peripheral Nerve Society. J Peripher Nerv Syst 15:79–92CrossRefGoogle Scholar
  32. 32.
    Rust S, Rosier M, Funke H, Real J, Amoura Z, Piette JC, Deleuze JF, Brewer HB, Duverger N, Denèfle P, Assmann G (1999) Tangier disease is caused by mutations in the gene encoding ATP-binding cassette transporter 1. Nat Genet 22:352–355PubMedCrossRefGoogle Scholar
  33. 33.
    Zyss J, Béhin A, Couvert P, Bouhour F, Sassolas A, Kolev I, Denys V, Vial C, Lacour A, Carrié A, Stojkovic T (2012) Clinical and electrophysiological characteristics of neuropathy associated with Tangier disease. J Neurol 259:1222–1226PubMedCrossRefGoogle Scholar
  34. 34.
    Björkhem I (2013) Cerebrotendinous xanthomatosis. Curr Opin Lipidol 24:283–287PubMedCrossRefGoogle Scholar
  35. 35.
    Ginanneschi F, Mignarri A, Mondelli M, Gallus GN, Del Puppo M, Giorgi S, Federico A, Rossi A, Dotti MT (2013) Polyneuropathy in cerebrotendinous xanthomatosis and response to treatment with chenodeoxycholic acid. J Neurol 260:268–274PubMedCrossRefGoogle Scholar
  36. 36.
    Bersano A, Lanfranconi S, Valcarenghi C, Bresolin N, Micieli G, Baron P (2012) Neurological features of Fabry disease: clinical, pathophysiological aspects and therapy. Acta Neurol Scand 126:77–97PubMedCrossRefGoogle Scholar
  37. 37.
    Bertelsen AK, Tøndel C, Krohn J, Bull N, Aarseth J, Houge G, Mellgren SI, Vedeler CA (2013) Small fibre neuropathy in Fabry disease. J Neurol 260:917–919PubMedCrossRefGoogle Scholar
  38. 38.
    Milone M, Massie R (2010) Polymerase gamma 1 mutations: clinical correlations. Neurologist 16:84–91PubMedCrossRefGoogle Scholar
  39. 39.
    Tang S, Dimberg EL, Milone M, Wong LJ (2012) Mitochondrial neurogastrointestinal encephalomyopathy (MNGIE)-like phenotype: an expanded clinical spectrum of POLG1 mutations. J Neurol 259:862–868PubMedCrossRefGoogle Scholar
  40. 40.
    Pareyson D, Piscosquito G, Moroni I, Salsano E, Zeviani M (2013) Peripheral neuropathy in mitochondrial disorders. Lancet Neurol. doi: 10.1016/S1474-4422(13)70158-3
  41. 41.
    Vallet AE, Verschueren A, Petiot P, Vandenberghe N, Nicolino M, Roman S, Pouget J, Vial C (2012) Neurological features in adult Triple-A (Allgrove) syndrome. J Neurol 259:39–46PubMedCrossRefGoogle Scholar
  42. 42.
    Houlden H, Smith S, De Carvalho M, Blake J, Mathias C, Wood NW, Reilly MM (2002) Clinical and genetic characterization of families with triple A (Allgrove) syndrome. Brain 125:2681–2690PubMedCrossRefGoogle Scholar
  43. 43.
    Synofzik M, Soehn AS, Gburek-Augustat J, Schicks J, Karle KN, Schüle R, Haack TB, Schöning M, Biskup S, Rudnik-Schöneborn S, Senderek J, Hoffmann KT, MacLeod P, Schwarz J, Bender B, Krüger S, Kreuz F, Bauer P, Schöls L (2013) Autosomal recessive spastic ataxia of Charlevoix Saguenay (ARSACS): expanding the genetic, clinical and imaging spectrum. Orphanet J Rare Dis 8:41PubMedCrossRefGoogle Scholar
  44. 44.
    Stevens JC, Murphy SM, Davagnanam I, Phadke R, Anderson G, Nethisinghe S, Bremner F, Giunti P, Reilly MM (2013) The ARSACS phenotype can include supranuclear gaze palsy and skin lipofuscin deposits. J Neurol Neurosurg Psychiatry 84:114–116PubMedCrossRefGoogle Scholar
  45. 45.
    Gazulla J, Benavente I, Vela AC, Marín MA, Pablo LE, Tessa A, Barrena MR, Santorelli FM, Nesti C, Modrego P, Tintoré M, Berciano J (2012) New findings in the ataxia of Charlevoix-Saguenay. J Neurol 259:869–878PubMedCrossRefGoogle Scholar
  46. 46.
    Girard M, Larivière R, Parfitt DA, Deane EC, Gaudet R, Nossova N, Blondeau F, Prenosil G, Vermeulen EG, Duchen MR, Richter A, Shoubridge EA, Gehring K, McKinney RA, Brais B, Chapple JP, McPherson PS (2012) Mitochondrial dysfunction and Purkinje cell loss in autosomal recessive spastic ataxia of Charlevoix-Saguenay (ARSACS). Proc Natl Acad Sci USA 109:1661–1666PubMedCrossRefGoogle Scholar
  47. 47.
    Prodi E, Grisoli M, Panzeri M, Minati L, Fattori F, Erbetta A, Uziel G, D’Arrigo S, Tessa A, Ciano C, Santorelli FM, Savoiardo M, Mariotti C (2012) Supratentorial and pontine MRI abnormalities characterize recessive spastic ataxia of Charlevoix-Saguenay. A comprehensive study of an Italian series. Eur J Neurol 20:138–146PubMedCrossRefGoogle Scholar

Copyright information

© Springer-Verlag Berlin Heidelberg 2013

Authors and Affiliations

  • Anna Sagnelli
    • 1
  • Giuseppe Piscosquito
    • 1
  • Davide Pareyson
    • 1
  1. 1.Clinic of Central and Peripheral Degenerative Neuropathies Unit, Department of Clinical Neurosciences, IRCCS Foundation“C. Besta” Neurological InstituteMilanItaly

Personalised recommendations